BioCentury

7:00 AM GMT, Aug 8, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

Lebrikizumab: Phase II data

The double-blind Phase II MILLY trial in 218 patients with asthma inadequately controlled with inhaled corticosteroids showed that subcutaneous lebrikizumab met the primary endpoint of significantly improving the mean relative change in FEV1 from baseline to week

Read the full 370 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.